← Every company
Ultragenyx Pharmaceutical Inc Lobbying
What Ultragenyx Pharmaceutical Inc discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.
RARE on carbonthat →Disclosed spend
$1.2M
across every filing on file
Filings
14
Years covered
1
Firms retained
4
What it lobbies about
Health IssuesGovernment IssuesMedical/Disease Research/Clinical LabsBudget/AppropriationsMedicare/Medicaid
14 filings
Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.
| Period | Lobbying for them | Disclosed |
|---|---|---|
| 20261st Quarter (Jan 1 - Mar 31) | ULTRAGENYX PHARMACEUTICAL INC.Health IssuesBudget/Appropriations | $440K |
| 20262nd Quarter (Apr 1 - June 30) | ULTRAGENYX PHARMACEUTICAL INC.Health IssuesBudget/Appropriations | $390K |
| 20262nd Quarter (Apr 1 - June 30) | MILLER STRATEGIES, LLCMedical/Disease Research/Clinical Labs | $140K |
| 20261st Quarter (Jan 1 - Mar 31) | MEHLMAN CONSULTING, INC.Health IssuesBudget/Appropriations | $60K |
| 20262nd Quarter (Apr 1 - June 30) | ALPINE GROUP PARTNERS, LLC.Health IssuesGovernment Issues | $60K |
| 20262nd Quarter (Apr 1 - June 30) | MEHLMAN CONSULTING, INC.Health IssuesBudget/Appropriations | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | ALPINE GROUP PARTNERS, LLC.Health IssuesGovernment Issues | $40K |
| 20262nd Quarter (Apr 1 - June 30) | FORBES-TATEHealth Issues | $30K |
| 20261st Quarter (Jan 1 - Mar 31) | FORBES-TATEHealth Issues | $10K |
| 20261st Quarter (Jan 1 - Mar 31) | ALPINE GROUP PARTNERS, LLC.Health IssuesGovernment Issues | — |
| 20261st Quarter (Jan 1 - Mar 31) | FORBES-TATEHealth Issues | — |
| 20261st Quarter (Jan 1 - Mar 31) | MILLER STRATEGIES, LLCMedical/Disease Research/Clinical Labs | — |
| 20261st Quarter (Jan 1 - Mar 31) | MILLER STRATEGIES, LLCMedical/Disease Research/Clinical Labs | — |
| 20261st Quarter (Jan 1 - Mar 31) | AVIVA STRATEGIES (FKA MGB CONSULTING)Health Issues | — |
A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.
More on RARE
Company overviewEverything on RARE in one place, with the price.SEC filingsWhat RARE's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat RARE's own officers and directors buy and sell.Planned salesSales RARE insiders have filed notice of.Who owns itEvery manager reporting a position in RARE.Funds holding itWhich funds and ETFs hold RARE, and how big a bet.Who lobbies for itThe lobbyists on RARE's account, and who they worked for.PatentsWhat RARE is filing at the patent office.